Lomitapide mesylate and lomitapide target ALDOA to inhibit growth and enhance gemcitabine efficacy in PDAC. (PubMed, iScience) - Apr 18, 2026 - "The observed synergistic or additive effects with gemcitabine depend on both specific PDAC cell line and chemical form of lomitapide, underscoring complexity of personalized combination therapies and need to consider drug properties and tumor biology. These findings support therapeutic repositioning of lomitapide mesylate and lomitapide for PDAC."
Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • ALDOA
|
|
Bai-Qiang Li; Chao Li; Fu-Ying Zhao; Hua-Qin Wang; Jia-Mei Wang; Shi-Yang Lu; Yan-Jie Liu
|